COVID Support

Sputnik V Manufacturing By Serum Institute Of India To Begin From September: RDIF

• BySheetal Sidhu     |    July 13, 2021

Russia’s sovereign wealth fund Russian Direct Investment Fund (RDIF) on Tuesday announced that it will work with the Serum Institute of India (SII) for the production of the Sputnik V vaccine to fight the COVID-19 pandemic. According to the official statement, the first batch of Sputnik V vaccines is expected to be produced at SII’s facilities in September. It is looking to produce over 300 million doses of the vaccine in India per year.

Adar Poonawalla, CEO of Serum Institute of India, said, “I am delighted to partner with RDIF to manufacture the Sputnik vaccine. We hope to make millions of doses in the coming months, with trial batches starting in September. With high efficacy and a good safety profile, it is critical that the Sputnik vaccine is accessible in full measure for people across India and the world. Given the uncertainty of the virus, it is important for international institutes and governments to collaborate and further bolster up our fight against the pandemic.”

“RDIF is delighted to cooperate with Serum Institute of India, the world’s largest vaccine manufacturer. This strategic partnership is a major step to substantially increase our production capabilities demonstrating a perfect example of joining forces and expertise to save lives both in India and around the world. With technology transfer underway we expect the first batches of the vaccine to be produced jointly with SII in coming months,” Kirill Dmitriev, CEO of the Russian Direct Investment Fund.

Follow Startup Story